Cushing Syndrome Clinical Trial
Official title:
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension
This Phase 3 study involves two phases, an open-label (OL) phase and a randomized-withdrawal (RW) phase. Patients will dose-escalate in 100 mg increments to a target dose of 400 mg orally once daily during the open-label phase. Patients will remain on open-label treatment until week 22 at which time they will be evaluated for the randomized-withdrawal phase based on pre-defined hyperglycemia and hypertension response criteria. Eligible patients will then be randomized to receive either relacorilant or placebo at a 1:1 ratio for 12 weeks. Patients who do not meet the criteria for randomization will end treatment and may be eligible to roll over into an extension safety study. Patients who complete the randomized-withdrawal phase of the study may also be eligible to roll over into an extension study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
| Recruiting |
NCT05881005 -
NAC- NAFLD And Cushing
|
N/A | |
| Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
| Terminated |
NCT03379363 -
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
|
||
| Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
| Recruiting |
NCT05911620 -
Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism
|
N/A | |
| Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
| Recruiting |
NCT04045015 -
Liquorice and Salivary Cortisol
|
N/A | |
| Recruiting |
NCT05804669 -
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|
||
| Recruiting |
NCT03343470 -
The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
|
||
| Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
| Terminated |
NCT02001051 -
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
|
Phase 2 | |
| Enrolling by invitation |
NCT03604198 -
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
|
Phase 2 | |
| Completed |
NCT05347979 -
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT01382420 -
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma
|
N/A | |
| Completed |
NCT00001849 -
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
|
Phase 2 | |
| Recruiting |
NCT06229405 -
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
|
||
| Recruiting |
NCT03211624 -
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
|
||
| Not yet recruiting |
NCT06326853 -
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
|